Figure 7.

BM ILC2s accelerate hematopoietic recovery after 5-FU treatment. ILC2s from WT, CAG-EGFP, or GM-CSF–KO mice were sorted and cultured in medium supplemented with 10 ng/ml IL-2 and 10 ng/ml IL-7 to expand cell number. Then, 2 × 10⁵ cells were intravenously injected into 150 mg/kg 5-FU–treated WT mice on days 1 and 2. (A) Schematic figure of the experiment. (B and C) WT mice were transferred with ILC2s from CAG-EGFP mice. On the day after the last transfer, the lodgment of EGFP⁺ cells in recipient BM was confirmed. (B) Snapshot of skull BM using two-photon microscopy. Green (arrowhead): EGFP⁺ ILC2; red: isolectin⁺ ECs. Scale bar, 100 µm. Results shown are representative of two independent experiments. (C) Flow cytometry plot of femur BM. Gated fraction represents homed EGFP⁺ ILC2s. Results shown are representative of two independent experiments. (D–G) WT mice were transferred with ILC2s from WT or GM-CSF–KO mice after 5-FU treatment. Control (Ctrl) mice were injected with PBS. The numbers of LSK (D), CMPs, GMPs, and MEPs (E), and Gr1⁺ or CD11b⁺ myeloid cells (F) from femurs and tibias, and WBC count in PB (G) were analyzed on day 7; n = 14 in control, n = 13 in WT ILC2s, and n = 8–10 in GM-CSF–KO ILC2s. Data are pooled from two independent experiments. In the bar charts, the results are shown as mean ± SEM, and each dot represents an individual mouse. Statistical significance was determined by ANOVA with the Bonferroni post hoc test (D–G).